Levofloxacin

C. diff Risk

High

Oral Bioavailability

Excellent

Spectrum Of Activity

Dosing

500-750mg PO/IV daily

0 - 20 eGFR20 - 50 eGFR50+ eGFR750mg IV/PO load then 500mg IV/PO q48h500-750mg IV/PO q48h500-750mg IV/PO daily

750mg IV/PO load then 500mg QHD

750mg IV/PO load then 500mg IV/PO q48h

General Information

Monitor QTc in patients with increased risk

QTc prolongation

Dysglycemia

CNS toxicity including confusion, psychosis

Tendinopathy and rupture

GI upset

Weakness exacerbation in myasthenia gravis

Rash

Other QTc prolonging agents

Di- & Trivalent cations including Al, Ca, Fe, Mg (antacids, dairy products, iron supplements, some enteral feeds) - decreased absorption

NSAIDs - increase seizure risk

Warfarin - increased INR

FDA Black Box warning against use in uncomplicated UTI, acute bacterial sinusitis, and acute exacerbation of chronic bronchitis where alternatives exist due to serious adverse side effects

May exacerbate muscle weakness in persons with myasthenia gravis. Avoid Use.

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 7.0

Biliary penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Lower respiratory infection (CAP, HAP), intraabdominal infection, UTI